140 related articles for article (PubMed ID: 7742591)
1. [Applications of antisense oligonucleotides in oncology].
Pierga JY; Cammilleri S; Benyahia B; Magdelénat H
Bull Cancer; 1994 Dec; 81(12):1023-42. PubMed ID: 7742591
[TBL] [Abstract][Full Text] [Related]
2. Applications of antisense oligonucleotides in oncology.
Pierga JY; Magdelenat H
Cell Mol Biol (Noisy-le-grand); 1994 May; 40(3):237-61. PubMed ID: 7920172
[TBL] [Abstract][Full Text] [Related]
3. Antisense oligonucleotides as therapeutics for malignant diseases.
Ho PT; Parkinson DR
Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689
[TBL] [Abstract][Full Text] [Related]
4. The zebrafish as a novel system for functional genomics and therapeutic development applications.
Nasevicius A; Ekker SC
Curr Opin Mol Ther; 2001 Jun; 3(3):224-8. PubMed ID: 11497344
[TBL] [Abstract][Full Text] [Related]
5. Not nonsense but antisense--applications of antisense oligonucleotides in different fields of medicine.
Oberbauer R
Wien Klin Wochenschr; 1997 Jan; 109(2):40-6. PubMed ID: 9123943
[TBL] [Abstract][Full Text] [Related]
6. [Basics of antisense oligonucleotide therapy and current therapeutical strategies in urology].
Kausch I; Böhle A
Aktuelle Urol; 2003 Dec; 34(7):458-68. PubMed ID: 14655082
[TBL] [Abstract][Full Text] [Related]
7. Perspectives on antisense therapy for the prevention of restenosis.
Kipshidze N; Moses J; Shankar LR; Leon M
Curr Opin Mol Ther; 2001 Jun; 3(3):265-77. PubMed ID: 11497351
[TBL] [Abstract][Full Text] [Related]
8. Antisense oligonucleotides strategy in the treatment of hypertension.
Kagiyama S; Kagiyama T; Phillips MI
Curr Opin Mol Ther; 2001 Jun; 3(3):258-64. PubMed ID: 11497350
[TBL] [Abstract][Full Text] [Related]
9. Antisense strategies for oncogene inactivation.
Stein CA; Benimetskaya L; Mani S
Semin Oncol; 2005 Dec; 32(6):563-72. PubMed ID: 16338422
[TBL] [Abstract][Full Text] [Related]
10. Antisense strategy in hematological malignancies.
Warzocha K
Cytokines Cell Mol Ther; 1999 Mar; 5(1):15-23. PubMed ID: 10390076
[TBL] [Abstract][Full Text] [Related]
11. [Antisense oligonucleotides are clinically tested. They inhibit the expression of disease-related genes].
Sommer W; Heilig M
Lakartidningen; 1999 Jan; 96(4):348-54. PubMed ID: 10024826
[TBL] [Abstract][Full Text] [Related]
12. Antisense effects in the cell nucleus: modification of splicing.
Kole R; Sazani P
Curr Opin Mol Ther; 2001 Jun; 3(3):229-34. PubMed ID: 11497345
[TBL] [Abstract][Full Text] [Related]
13. Apoptosis, Bcl-2 antisense, and cancer therapy.
Piro LD
Oncology (Williston Park); 2004 Nov; 18(13 Suppl 10):5-10. PubMed ID: 15651171
[TBL] [Abstract][Full Text] [Related]
14. Oligonucleotide therapeutics: clothing the emperor.
Gewirtz AM
Curr Opin Mol Ther; 1999 Jun; 1(3):297-306. PubMed ID: 11713794
[TBL] [Abstract][Full Text] [Related]
15. Molecular therapy to inhibit NFkappaB activation by transcription factor decoy oligonucleotides.
Morishita R; Tomita N; Kaneda Y; Ogihara T
Curr Opin Pharmacol; 2004 Apr; 4(2):139-46. PubMed ID: 15063357
[TBL] [Abstract][Full Text] [Related]
16. Making sense of antisense.
Vidal L; Blagden S; Attard G; de Bono J
Eur J Cancer; 2005 Dec; 41(18):2812-8. PubMed ID: 16289851
[TBL] [Abstract][Full Text] [Related]
17. siRNA-based approaches in cancer therapy.
Devi GR
Cancer Gene Ther; 2006 Sep; 13(9):819-29. PubMed ID: 16424918
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis C IRES: translating translation into a therapeutic target.
Jubin R
Curr Opin Mol Ther; 2001 Jun; 3(3):278-87. PubMed ID: 11497352
[TBL] [Abstract][Full Text] [Related]
19. Nucleic acid-based modulation of cardiac gene expression for the treatment of cardiac diseases. Approaches and perspectives.
Poller W; Fechner H; Kurreck J; Pauschinger M; Kühl U; Erdmann VA; Lamers JM; Schultheiss HP
Z Kardiol; 2004 Mar; 93(3):171-93. PubMed ID: 15024585
[TBL] [Abstract][Full Text] [Related]
20. [Antisense constructs, therapeutics of the future?].
Van Aerschot A
Verh K Acad Geneeskd Belg; 2000; 62(6):565-601. PubMed ID: 11196580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
